Home PMPRB

Keyword: PMPRB

9 results found

The 10 highest-cost drugs reimbursed by public drug plans in Canada in the 2021/22 fiscal year were all rare disease treatments with annual treatment costs of more than $250,000, according to a new report by the Patented Medicine Prices Review Board. It found the increased use of high-cost drugs continued to be the main factor […]

Copyright_olegback_123RF

An article on the 2023 Benefits Canada Healthcare Survey’s findings on plan members’ appreciation of health benefits was the most-read story on BenefitsCanada.com over the last week. Here are the five most popular news stories of the week: 1. 72% of plan members appreciate health benefits more today than before pandemic: survey 2. 54% of benefits plan members currently live […]

  • By: Staff
  • September 22, 2023 September 21, 2023
  • 09:00

A recent report by the Patented Medicine Prices Review Board shows increased growth for private drug plan costs but promising pharmaceutical innovation, says Joe Farago, executive director of private payers and investment at Innovative Medicines Canada. The report also found the number of new medicines launched in Canada was higher than the median for Organisation for […]

  • By: Sadie Janes
  • September 20, 2023 September 20, 2023
  • 09:00
2020 Drug Plan Trends Report: Developments, data and design

The growth of gene and cell therapies are raising significant questions among private payers about who bears the responsibility for the costs of these treatments, says Tim Clarke, president at TC Health Consulting Inc. “One issue is whether this is going to be paid for by public health or if it’s an employer health issue. […]

As the coronavirus pandemic enters its fourth year, it’s perhaps unsurprising that the health crisis has taken its toll on employee mental health. Scotiabank saw a notable rise in claims for mental-health drugs in 2022, says Ayman Alvi, the bank’s vice-president of global pension and benefits, noting the increased use of these medications aligns with […]

The increasing use of high-cost medicines is the primary cost driver for all Canadian drug plans, according to a new report by the Patented Medicine Prices Review Board. It found drug costs for public plans rose by 5.3 per cent in 2019/20, with high-cost medicines accounting for 6.3 per cent of the increase. Among private […]

  • By: Staff
  • November 25, 2022 November 24, 2022
  • 09:00

The amendments to the Patented Medicine Prices Review Board regulations are officially taking effect July 1, after being delayed multiple times. The changes, which were originally proposed in 2019, are the first significant update to the regulations in more than 30 years. After consulting with stakeholders, Health Canada will be moving forward with the implementation of […]

Copyright_ilixe48_123RF

An announcement regarding long-awaited amendments to the Patented Medicines Review Board regulations was the most-read story on BenefitsCanada.com over the last week. Here are the five most popular news stories of the week: 1. PMPRB drug pricing regulations officially coming into effect this July 2. Key stakeholders highlighting value of private payer health care amid plans for […]

  • By: Staff
  • April 22, 2022 April 21, 2022
  • 09:00

This month marks the second anniversary of the beginning of the coronavirus pandemic, a 24-month span that has had profound effects on the health of benefits plan members and the status and structure of their plans. For drug plans in particular, several trends have come to light — or have accelerated — during the course […]